Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

RoActemra®

Known as: RoActemra 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Differential role of Interleukin-1 and Interleukin-6 in K-Ras-driven pancreatic carcinoma undergoing mesenchymal transition
ABSTRACT K-Ras mutations are a hallmark of human pancreatic adenocarcinoma (PDAC) and epithelial-mesenchymal-transition (EMT) is… Expand
2018
2018
A Case of Adult-Onset Still’s Disease Caused by a Novel Splicing Mutation in TNFAIP3 Successfully Treated With Tocilizumab
TNFAIP3 encodes the NF-κB regulatory protein A20. High-penetrance heterozygous mutations in TNFAIP3 cause a haploinsufficiency of… Expand
Review
2017
Review
2017
Tocilizumab: A Review in Rheumatoid Arthritis
Intravenous (IV) and subcutaneous (SC) tocilizumab (RoActemra®), an IL-6 receptor antagonist, are approved (± methotrexate) in… Expand
  • table 1
  • table 2
  • table 3
2017
2017
Gr upSM Interleukin-6 as a Therapeutic Target on Human Cancer
Interleukin-6 (IL-6) is a proinflammatory cytokine produced by various cells. Emerging evidence shows that IL-6 plays critical… Expand
  • table 1
2017
2017
Anti-carbamylated protein antibodies precede disease onset in monkeys with collagen-induced arthritis
BackgroundRheumatoid factor (RF), anti-citrullinated protein antibodies (ACPA) and anti-carbamylated protein (anti-CarP… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
2014
2014
FRI0317 Act-Axis Study: Impact of Roactemra® (TOCILIZUMAB) on Fatigue and Related Factors in Patients with Arthritis Rheumatoid in Daily Clinical Practice in Spain
Background Fatigue is a reliable and sensitive measure to change in rheumatoid arthritis (RA) whose contribution to disease… Expand
2013
2013
FRI0323 Prospective Follow-Up of Tocilizumab Treatment in 1503 Patients with Refractory Rheumatoid Arthritis: Tolerance Data at 1 Year from the French Registry Regate (Registry – Roactemra)
Objectives To assess tolerance and safety of rheumatoid arthritis (RA) treatment by tocilizumab (TCZ) in real life Methods The… Expand
Highly Cited
2012
Highly Cited
2012
Is Tocilizumab an Effective Option for Treatment of Refractory Uveitis Associated with Juvenile Idiopathic Arthritis?
To the Editor: Anti-interleukin 6 receptor (anti-IL-6R) antibodies have been effective in experimental models of autoimmune… Expand
Review
2011
Review
2011
Tocilizumab: A Novel Humanized Anti-Interleukin 6 Receptor Antibody for the Treatment of Patients with Rheumatoid Arthritis
  • R. Alten
  • Therapeutic advances in musculoskeletal disease
  • 2011
    • Corpus ID: 8591212
Tocilizumab (TCZ; RoActemra® or Actemra®) is a recombinant humanized monoclonal antibody that acts as an interleukin 6 (IL-6… Expand
  • table 1
  • table 2
  • figure 1
  • table 8
  • table 7
Review
2009
Review
2009
▼Tocilizumab for rheumatoid arthritis
▼Tocilizumab (RoActemra – Roche) is a new biological agent available in the UK for the treatment of adults with rheumatoid… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE